Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ALK wild-type TP53 P177T |
Therapy | Crizotinib + Cyclophosphamide + Topotecan |
Indication/Tumor Type | neuroblastoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK wild-type TP53 P177T | neuroblastoma | no benefit | Crizotinib + Cyclophosphamide + Topotecan | Preclinical - Cell culture | Actionable | In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783). | 26438783 |
PubMed Id | Reference Title | Details |
---|---|---|
(26438783) | Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. | Full reference... |